PT  - JOURNAL ARTICLE
ED  - , 
TI  - The CAR-T Therapy Tisagenlecleucel Is Safe in Secondary CNS Lymphoma
AID  - 10.1158/2159-8290.CD-RW2019-116
DP  - 2019 Jul 26
TA  - Cancer Discovery
4099  - http://cancerdiscovery.aacrjournals.org/content/early/2019/07/26/2159-8290.CD-RW2019-116.short
4100  - http://cancerdiscovery.aacrjournals.org/content/early/2019/07/26/2159-8290.CD-RW2019-116.full
AB  - Tisagenlecleucel has an acceptable safety profile and showed preliminary evidence of CNS efficacy.